5-hexylthio-4-[3,5-bis(1,1-dimethylbutyl)-4-hydroxyphenyl]-1,2-dithiole-3-thione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-hexylthio-4-[3,5-bis(1,1-dimethylbutyl)-4-hydroxyphenyl]-1,2-dithiole-3-thione
• 英文别名: 5-Hexylsulfanyl-4-[4-hydroxy-3,5-bis(2-methylpentan-2-yl)phenyl]dithiole-3-thione
• 化学式: C₂₇H₄₂OS₄
• 分子量: 510.894
• InChiKey: DEWLHKXZTWRMFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11
• 重原子数：
  32
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
  申请人：Patrick Prendergast

  公开号：US20040053989A1

  公开（公告）日：2004-03-18

  The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to patients, or delivering to the tissues of such patients, oltipraz or related compounds as disclosed in the specification.

  该发明提供了治疗神经系统疾病，如阿尔茨海默病的方法，或减缓这些疾病的进展，或治疗和/或预防其他疾病的方法，通过向患者或向这些患者的组织输送在规范中披露的oltipraz或相关化合物。
• COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS
  申请人：Prendergast, Patrick T.

  公开号：EP2134347A2

  公开（公告）日：2009-12-23
• Compositions and Methods for Preventing and Treating Mucositis and Weight Loss
  申请人：Cascade Estate Ltd.

  公开号：US20130259930A1

  公开（公告）日：2013-10-03

  Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.
• [EN] DITHIOLTHIONE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND FOR MEMORY ENHANCEMENT<br/>[FR] COMPOSES DITHIOLTHIONE POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET POUR RENFORCER LA MEMOIRE
  申请人：PRENDERGAST PATRICK T

  公开号：WO2001009118A2

  公开（公告）日：2001-02-08

  The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to patients, or delivering to the tissues of such patients, oltipraz or related compounds as disclosed in the specification.
• [EN] COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR PRÉVENIR ET TRAITER L'INFLAMMATION D'UNE MUQUEUSE ET LA PERTE DE POIDS
  申请人：PRENDERGAST PATRICK T

  公开号：WO2008110585A2

  公开（公告）日：2008-09-18

  [EN] A method for prophylaxis and/or treatment of mucositis comprising the steps of providing a therapeutically effective amount of a composition comprising either (1) at least one compound selected from the group consisting of 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; or (2) a cytokinin compound; and administering the composition to a subject in need of such treatment. Also provided are pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3- thione and/or a cytokinin compound and use of these compositions in the preparation of a medicament for the treatment and/or prophylaxis of mucositis. The cytokinin compound may be selected from, but is not limited to N⁶-isopentenyl adenosine and N⁶-benzyl adenosine. The compositions may further comprise a chemotherapeutic agent, such as cisplatin. Further provided are methods and compositions for reducing and/or preventing weight loss in subjects undergoing cancer treatment.
  [FR] L'invention porte sur un procédé pour la prophylaxie et/ou le traitement de l'inflammation d'une muqueuse comprenant les étapes consistant à se procurer une quantité thérapeutiquement efficace d'une composition comprenant soit (1) au moins un composé choisi dans le groupe constitué par le 5-[2-pyrazinyl]-4-méthyl-1,2-3-thione ou un analogue, dérivé, métabolite, promédicament, solvate ou sel pharmaceutiquement acceptable de celui-ci; soit (2) un composé cytokinine; et à administrer la composition à un sujet nécessitant un tel traitement. L'invention porte également sur des compositions pharmaceutiques comprenant le 5-[2-pyrazinyl]-4-méthyl-1,2-3-thione et/ou un composé cytokinine et sur une utilisation de ces compositions dans la préparation d'un médicament pour le traitement et/ou la prophylaxie de l'inflammation d'une muqueuse. Le composé cytokinine peut être sélectionné parmi, mais sans y être limité, la N⁶-isopentényl adénosine et la N⁶-benzyl adénosine. Les compositions peuvent en outre comprendre un agent chimiothérapeutique, tel que la cisplatine. L'invention porte en outre sur des procédés et des compositions pour réduire et/ou prévenir la perte de poids dans des sujets subissant un traitement du cancer.